Treatment withdrawal for any reason Duration of treatment (range): 12 (3 months) to 36 weeks · people (aged 10–64 years) with drug‐resistant focal epilepsy
It is very uncertain whether vigabatrin changes treatment withdrawal for any reason Duration of treatment (range):… compared with placebo (very low certainty).
1 finding from 1 review
Ataxia · people (aged 10–64 years) with drug‐resistant focal epilepsy
It is very uncertain whether vigabatrin changes adverse effects: ataxia Duration of treatment (range): 7–36 weeks compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: dizziness, lightheadedness · people (aged 10–64 years) with drug‐resistant focal epilepsy
Vigabatrin may leads to higher adverse effects: dizziness/light‐headedness Duration of treatment… compared with placebo (low certainty).
1 finding from 1 review
Adverse effect: fatigue · people (aged 10–64 years) with drug‐resistant focal epilepsy
Vigabatrin may leads to higher adverse effects: fatigue Duration of treatment (range): 8–36 weeks compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: nystagmus Duration of treatment (range): 16–18 weeks · people (aged 10–64 years) with drug‐resistant focal epilepsy
Vigabatrin showed no clear difference in adverse effects: nystagmus Duration of treatment (range): 16–18 weeks compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: abnormal vision Duration of treatment (range): 8–36 weeks · people (aged 10–64 years) with drug‐resistant focal epilepsy
It is very uncertain whether vigabatrin changes adverse effects: abnormal vision Duration of treatment (range): 8–36… compared with placebo (very low certainty).
1 finding from 1 review
Mean intraocular pressure · children at or before five years of age with primary congenital glaucoma
1 finding from 1 review
Proportion of participants with IOP≤ 21 mmHg, with or without ocular hypotensive medications 1 year · children at or before five years of age with primary congenital glaucoma
It is very uncertain whether combined trabeculotomy with trabeculectomy changes surgical success: proportion with postoperative IOP ≤ 21 mmHg with… compared with trabeculotomy (very low certainty).
1 finding from 1 review
Mean IOP ( · children at or before five years of age with primary congenital glaucoma
1 finding from 1 review
Proportion with postoperative IOP ≤ 21 mmHg (surgical success) with or without glaucoma medications 6 months after surgery · children at or before five years of age with primary congenital glaucoma
It is very uncertain whether viscotrabeculotomy changes proportion with postoperative IOP ≤ 21 mmHg (surgical success) with… compared with conventional trabeculotomy (very low certainty).
1 finding from 1 review
Hyphema · children at or before five years of age with primary congenital glaucoma
Viscotrabeculotomy showed no clear difference in adverse outcomes—hyphema Up to 6 months after surgery compared with conventional trabeculotomy (low certainty).
1 finding from 1 review
Mean IOP ( · children at or before five years of age with primary congenital glaucoma
1 finding from 1 review
Proportion of participants with IOP≤ 21 mmHg, with or without ocular hypotensive medications 1 year · children at or before five years of age with primary congenital glaucoma
Microcatheter‐assisted trabeculotomy probably leads to higher proportion with postoperative IOP ≤ 21 mmHg (surgical success) with… compared with conventional trabeculotomy (moderate certainty).
1 finding from 1 review
Hyphema · children at or before five years of age with primary congenital glaucoma
Microcatheter‐assisted trabeculotomy probably leads to higher adverse outcomes— hyphema Up to 1 year after surgery compared with conventional trabeculotomy (moderate certainty).
1 finding from 1 review
Change in weight (kg) · children aged 7 years or over and adults with cystic fibrosis
1 finding from 1 review
Change in height · children aged 7 years or over and adults with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in BMI · children aged 7 years or over and adults with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Abdominal pain frequency or change in frequency · children aged 7 years or over and adults with cystic fibrosis
1 finding from 1 review
CFA: change from baseline (%) · children aged 7 years or over and adults with cystic fibrosis
1 finding from 1 review
Adverse events · children aged 7 years or over and adults with cystic fibrosis
1 finding from 1 review